We describe the enzymes that constitute the major bradykinin (BK)-processing pathways in the perfusates of mesenteric arterial bed (MAB) and coronary vessels isolated from Wistar normotensive (WNR) and spontaneously hypertensive (SHR) rats.
Introduction
The nonapeptide bradykinin (BK) has important pharmacological effects on blood vessels, heart and kidney; among these, the most conspicuous is the transient hypotensive effect elicited by the administration of BK into the systemic circulation of all species studied (3). BK circulates in the low nanomolar range, a concentration two orders of magnitude lower than that needed to decrease blood pressure (27) Perfused isolated heart preparation: The heart was rapidly removed and mounted on a modified Langendorff apparatus, and perfused through a cannula inserted into the aorta with 100 mL of the above mentioned Krebs' solution containing 2 mmol/L sodium pyruvate. The perfusion was carried out at a flow rate of 10 or 8 mL/min in hearts isolated from WNR or SHR, respectively. Under these conditions, the isolated hearts showed stable heart rate and ventricular contractility for at least 2 h. After a 10-min period of stabilization with input of fresh Krebs' solution to ensure thorough removal of blood substances from the preparation, the piping connections of the perfusion setup were altered so to keep approximately 125 mL of perfusing solution recirculating through the coronary bed during 2 h. The perfusate was then recovered and its volume reduced to 0.5 mL, corresponding to a 250-fold concentration of its protein content, by using an -BK per min using BK as the substrate, under the described conditions.
Basic carboxypeptidase purification:
The enzyme was purified by a combination of affinity chromatographies on PCI-Sepharose (40) and Arg-Sepharose (38) columns.
Briefly, a solution of concentrated high molecular weight substances of eight pooled perfusates in 5 mL of equilibrating buffer (10 mmol/L Tris-HCl buffer, pH 7.5, containing 0.5 mol/L NaCl) was loaded on a PCI-Sepharose (8 x 20 mm) at room temperature, at a flow rate of 0.3 mL/min. After removal of unbound material and washing of the column with 10 mL of equilibrating solution, the absorbed enzymes were recovered by percolating a 100 mmol/L Na 2 CO 3 solution, pH 11.4, through the column. Samples of 0.7 mL were collected throughout the experiment, whose pHs were lowered to about 7.5 by addition of 1.0 mol/L Tris-HCl buffer, pH 7.0, as required. The fractions that had des- 
PCR amplification of reverse transcribed mRNA (RT-PCR):
Total RNA was extracted from rat mesentery, pancreas, kidney, liver, lung, heart, aorta and carotid using the Trizol reagent, following the manufacturer instructions (Invitrogen, Carlsbad, CA, USA). . Thus, these results strongly suggest that the basic carboxypeptidase isolated from the rat MAB perfusate is identical with the pancreatic CPB. Moreover, none of these fragments were found in the rat TAFI, also known as rat plasma CPB, sequence (GenBank Protein database accession number NP_446069).
Tissue distribution of mRNA encoding rat CPB: The expression of CPB mRNA was investigated in some of the rat tissues using RT-PCR ( Figure 6 ). This procedure, using the specific CPB oligonucleotides described in Methods, amplified DNA fragments from total RNA extracts from the indicated tissues whose sizes matched the predicted value of 1248 bp previously described for rat pancreas pre-proCPB (16) . No PCR products were detected when sterile water was a substitute for the respective cDNA in the reaction (not shown). CPB mRNA was highly expressed in mesentery, pancreas, liver, and kidney but its expression was below detection level in lung, heart, aorta and carotid artery.
Discussion
Comparison between the kininase activities detected in the rat MAB and coronary perfusates revealed two prominent differences concerning their proteolytic capacities and specificities. Firstly, it was shown that an individual rat MAB secretes, on the average, 250-fold more kininase activity per min than its coronary counterpart; secondly, BK was cleaved almost exclusively at the Phe (11, 12) , are present in small quantities in the coronary perfusates of WNR and SHR, the former having also a so far unidentified BK(1-5)-forming enzyme whose specificity resembles that of neurolysin or thimet oligopeptidase (21) . The specificities of these BK-destroying proteases present in the rat coronary perfusate are consistent with the products formed in previously described pathways of BK degradation studied in different isolated rat heart preparations (1,7,25); the pentapeptide BK(1-5), a major fragment formed by the action of coronary perfusate on BK, has also been shown to be a stable end-product of BK degradation in human plasma (19) . Although we did not characterize the kininases -BK-forming enzyme of the MAB perfusate was first described as a CPN-like after two of its readily observable features, namely, its occurrence as a soluble protease in the perfusate and its proteolytic activity toward the substrates hippuryl-Lys and BK (23) . In the present work we extended the enzymological characterization of the des-Arg 9 -BK-forming enzyme of the MAB perfusate by using some inhibitors for basic carboxypeptidases, among which MGTA and PCI. Whereas CPN is known to be inhibited by MGTA (30) but refractory to CPI treatment (34), the basic carboxypeptidase of the rat MAB was inhibited by both compounds, setting a clear distinction between these two enzymes. Indeed, the latter enzyme could be isolated in good yield and highly purified form by a procedure that involved affinity chromatography over PCI-Sepharose column (Figure 4) . The amino acid sequence of the purified protein was shown to be identical with that of the rat pancreatic CPB by screening a tryptic peptide mass fingerprint of the enzyme against a tryptic fragment database derived from information of NCBI and Swiss-Prot databases (24) . Thus, contrary to the general belief that CPB is a digestive protease whose production is restricted to the pancreas and that does not participate in regulatory processes (34, 37, 39) , we found that it is the major BKprocessing enzyme of the rat MAB perfusate. The rat MAB perfusate CPB shares some similarities with human and rat activated TAFI regarding its solubility, structure and specificity toward synthetic substrates and inhibitors (8, 14, 20) . Despite these biochemical similarities, any functional overlap between rat MAB perfusate CPB and activated TAFI remains to be established; activated TAFI is also known as plasma CPB, CPU or CPR. During our studies we also observed that the expression of CPB mRNA was of the same order of magnitude in rat liver, mesentery, kidney and pancreas, whose corresponding amplicons were of identical sizes, but very low in lung, heart, aorta and carotid artery (Figure 6) . A relatively high level of expression of CPB mRNA in mesentery compared with that in heart correlates well with the CPB activities found in rat MAB and coronary perfusates, respectively ( Figures 1A and 2A) . Another example of a prototypical digestive enzyme that seems to participate in regulatory processes is rat elastase-2, produced by endothelial cells of the rat MAB as a highly specific angiotensin II-forming enzyme (29, 30) . Although there has been no direct evidence that CPB functions as a vasopeptidase in vivo, two reports have raised this possibility. It has been proposed that human serum would contain either small quantities of a CPB-like enzyme or a co-factor capable of augmenting about five times the activity of plasma CPN to account for the actual serum des-Arg 9 -BK-forming activity (31); indeed, CPB is known to remove the C-terminal Arg residue of BK far more readily than CPN (9) . A second report that suggests that CPB might also function as a regulatory enzyme is the one that describes a significant linkage between the locus of CPB on chromosome 2 in the Lyon hypertensive rat strain and the pulse pressure component of blood pressure regulation (6); despite this genetic linkage, experimental evidences demonstrating the involvement of CPB in this process remains to be established. Although the precise physiological roles for the soluble basic carboxypeptidases described here are not certain at present, a reasonable hypothesis is that they play a role in the processing of bioactive peptides to meet the metabolic requirements of different tissues, as suggested by the wide difference in the distribution of these enzymes in rat MAB and coronary perfusates. 
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